On Thursday, Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX), declined -4.75% to $168.87.
Valeant Pharmaceuticals International, declared that it has accomplished the formerly declared acquisition of Synergetics USA , Inc.. Synergetics is a leading supplier of precision surgical devices. Synergetics’ primary focus is on the surgical disciplines of ophthalmology and neurosurgery.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide.
On other hand, Shares of Johnson & Johnson (NYSE:JNJ), gained 2.77% to $97.15.
Johnson & Johnson shares are trading 2.48% above their 50-day moving average, and -1.07% below their 200-day moving average. The stock recently closed at market price of $97.15 with a 1 year price target of $108.77. It is up 1.77% over 12 months and trades at 15.16 times forward earnings.
Johnson & Johnson, declared sales of $17.1 billion for the third quarter of 2015, a decrease of 7.4% as contrast to the third quarter of 2014. Operational sales results raised 0.8% and the negative impact of currency was 8.2%. Domestic sales reduced 0.6%. International sales reduced 13.7%, reflecting operational growth of 2.1% and a negative currency impact of 15.8%. Not Taking Into Account the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales raised 5.6%, domestic sales raised 7.7% and international sales raised 3.8%. The Company also declared its Board of Directors has approved the repurchase of up to $10 billion of the company’s common stock.
“New and core products drove solid underlying growth for Johnson & Johnson in the quarter,” said Alex Gorsky, Chairman and Chief Executive Officer. “Consistent with the plans we’ve laid out for the year, we’re focusing our portfolio and are advancing our innovation agenda to expand our leadership position in key categories while seeking new opportunities for growth. Our dedicated employees are committed to improving healthcare and making a difference in the lives of patients and consumers worldwide.”
The Company raised its adjusted earnings guidance for full-year 2015 to $6.15 - $6.20 per share. The Company’s guidance excludes the impact of after-tax intangible amortization expense and special items.
Johnson & Johnson, together with its auxiliaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.
